Europe Molecular Diagnostics Market Primed to Surpass $13.25 Billion by 2030

Meticulous Research®, a leading provider of market intelligence solutions, unveils its latest report forecasting the trajectory of the Europe Molecular Diagnostics Market. Titled “Europe Molecular Diagnostics Market by Product, Test Type, Technology, Application, and End User—Forecast to 2030,” the report anticipates a robust market value of $13.25 billion by 2030, reflecting a steady CAGR of 4.0% from 2023 to 2030.

Market Overview

Molecular diagnostics, a groundbreaking field analyzing DNA or RNA sequences for potential diseases, heralds a new era in healthcare. These tests, which pinpoint gene mutations associated with specific diseases, facilitate early diagnosis and targeted treatments. The market’s growth is propelled by technological advancements, the rising adoption of point-of-care (PoC) diagnostic tests, escalating R&D investments, a burgeoning geriatric populace, and the increasing incidence of target diseases.

Download Free Sample Report:

Opportunities and Challenges

While the market brims with opportunities, challenges such as regulatory hurdles and the high costs of molecular diagnostic tests temper its growth. Nonetheless, developments in companion diagnostics offer promising growth avenues. However, the scarcity of skilled professionals poses a formidable challenge to market expansion.

Key Players and Strategic Developments

Leading market players such as F. Hoffmann-La Roche Ltd, Hologic, Inc., QIAGEN N.V., Danaher Corporation, bioMérieux S.A., Becton, Dickinson and Company (BD), Siemens Healthineers AG, DiaSorin S.p.A., Abbott Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Illumina, Inc. have spearheaded key strategic initiatives to bolster their market presence.

Browse in depth @

New Molecular Diagnostics Products Amid the COVID-19 Pandemic

The COVID-19 pandemic precipitated a surge in demand for diagnostic products, prompting diagnostic companies to launch specific products for researching COVID-19 variants. Notable launches include F. Hoffmann-La Roche Ltd’s COVID-19 test for detecting subvariant BA.2.75 and DiaSorin S.p.A.’s Simplexa SARS-CoV-2 Variants Direct assay. These developments underscore the market’s resilience amidst unprecedented challenges.

Market Segmentation and Insights

The report provides a comprehensive segmentation of the Europe molecular diagnostics market, analyzing various parameters such as product & service, test type, technology, application, end-user, and geography. Key segments include kits & reagents, PoC tests, PCR technology, infectious diseases testing, and hospitals & clinics.

Request Free Research Report Sample:

Market Growth Projections

Among the segments, kits & reagents are poised to witness the fastest growth, fueled by the increasing prevalence of chronic and infectious diseases and the expansion of disease-specific assay portfolios. Similarly, the PoC segment is expected to register rapid growth, driven by technological advancements and the shift towards decentralized molecular testing.

Geographic Insights

Germany is anticipated to dominate the Europe molecular diagnostics market, buoyed by its patient-centric approach, elderly population predisposed to chronic diseases, and heightened demand for diagnostic tests during the COVID-19 pandemic.

Quick Buy @


Contact Us:

Mr. Khushal Bombe

Meticulous Market Research Inc.

1267 Willis St, Ste 200 Redding,

California, 96001, U.S.

USA: +1-646-781-8004

Europe : +44-203-868-8738

APAC: +91 744-7780008

Email- [email protected]

Visit Our Website:

Connect with us on LinkedIn-